GT Biopharma, Inc. (GTBP) vs Phio Pharmaceuticals Corp. (PHIO)

GT Biopharma, Inc. and Phio Pharmaceuticals Corp. are both Biotechnology companies. GT Biopharma, Inc. and Phio Pharmaceuticals Corp. are of similar size ($9.4M and $9.3M). Phio Pharmaceuticals Corp. has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. Phio Pharmaceuticals Corp. grew revenue faster over the last twelve months: 79.0% against −76.2%. Across the 13 metrics below, Phio Pharmaceuticals Corp. leads on 8 and GT Biopharma, Inc. on 5.

Valuation

Metric GTBP PHIO Biotechnology median
P/E 0.81 n/m 10.26
P/S 121.89 68.34 9.18
P/B 2.05 0.74 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 0.26 0.65
EV/Sales 482.71 (25.52) 8.98
Earnings yield 122.77% (174.15%) (34.89%)
Free cash flow yield (194.98%) (131.34%) (24.52%)

Profitability

Metric GTBP PHIO Biotechnology median
Gross margin 41.67% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 102.03% (113.71%) (50.12%)
Return on assets (176.27%) (100.78%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GTBP PHIO Biotechnology median
Revenue growth (TTM) (76.19%) 78.95% 6.26%
EPS growth (last fiscal year) 3.75% 84.03% 29.88%
Revenue growth, 5-year CAGR 19.67% (21.62%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GTBP PHIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.61 8.39 4.89
Net debt to EBITDA 0.56 2.28 1.01

Dividend

Metric GTBP PHIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GTBP PHIO Biotechnology median
Market cap 9.36m 9.30m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack